<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between February 1991 and April 1994 induction chemotherapy of 32 adult consecutive patients under 65 years with de novo <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) was started in the study UHKT-911 </plain></SENT>
<SENT sid="1" pm="."><plain>They were 19 women and 13 men, aged 18-63 (median 44) years </plain></SENT>
<SENT sid="2" pm="."><plain>Their <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were classified according to the FAB classification: 3 M0, 3 M1, 9 M2, 14 M4, 3 M5 </plain></SENT>
<SENT sid="3" pm="."><plain>Induction chemotherapy consisted of 1-2 cycles with 3-4 doses of <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> (DNR) 45 mg/m2/d i.v. and 14 doses of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) 200 mg/m2 per 3-h infusion every 12 hours </plain></SENT>
<SENT sid="4" pm="."><plain>After the treatment patients, not being in complete remission, got the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> cycle with 10 high-doses of Ara-C 2000 mg/m2 per 3-h infusion every 12 hours i.v. and DNR 45 mg/m2/d i.v. on days 4 and 5, then the EMi cycle composed of <z:chebi fb="0" ids="4911">etoposide</z:chebi> 100 mg/m2/d i.v. for 5 days and mitozantrone 10-12 mg/m2/d i.v. on days 1, 3 and 5 </plain></SENT>
<SENT sid="5" pm="."><plain>Complete remission (CR) was achieved in 25 of 32 (78%) patients after 1-3 cycles </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients died between days 5 and 24 of treatment of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, two patients were resistant to 4 cycles of induction therapy and survived 8.4 and 13.5 months </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients chose allogeneic bone marrow transplantation in their 1st CR from their relatives </plain></SENT>
<SENT sid="8" pm="."><plain>Two of them have been living in CR for 115 a 110 months since diagnosis, the third died of <z:hpo ids='HP_0100806'>sepsis</z:hpo> on the day 52 after transplantation </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients in CR died of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> after their 2nd. consolidation cycle </plain></SENT>
<SENT sid="10" pm="."><plain>Twenty patients in CR completed 2-4 consolidation cycles (1-3 HD, 1 EMi) </plain></SENT>
<SENT sid="11" pm="."><plain>Median of their CR duration was 17.8 (2-117) months </plain></SENT>
<SENT sid="12" pm="."><plain>Relapse appeared in 12 cases after 4.4-34.8 (median 12.5) months, 8 patients (6 women and 2 men, aged 29-63 years) have remained longer than 5 years in their 1st </plain></SENT>
<SENT sid="13" pm="."><plain>CR </plain></SENT>
<SENT sid="14" pm="."><plain>Cytogenetic examination of their bone marrow showed a <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype in 4 cases, 1x 46,XX,del(1)(p32p34), 1x 46,XX,16p+, 1x 47,XX,+mar, 1x 46,XX,del(5)(q22q33) </plain></SENT>
<SENT sid="15" pm="."><plain>After 62 months in CR a <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> with dysplastic bone marrow changes developed in one of them, probably a secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, lasting for further 33 months </plain></SENT>
<SENT sid="16" pm="."><plain>Event-free survival at 5 years was 27.5% (8/29 patients), significantly better (p = 0.046) against 7.5% (3/40) patients treated without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> cycles in the years 1982-1987 </plain></SENT>
<SENT sid="17" pm="."><plain>The same difference was observed in 7.5-year overall survival (p = 0.036) between the two studies, when 3 of 6 patients 60-64 years old remain in their 1 </plain></SENT>
<SENT sid="18" pm="."><plain>CR </plain></SENT>
</text></document>